MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Taranabant

CAS No. : 701977-09-5

MCE 站：Taranabant

产品活性：Taranabant 是一种有效的选择性的 cannabinoid 1 (CB1) 受体反向激动剂，抑制结合和多种激动剂的功能活性，作用于人 CB1R，K_i 为 0.13 nM。

研究领域：GPCR/G Protein  |  Neuronal Signaling

作用靶点：Cannabinoid Receptor

In Vitro: Taranabant (MK-0364) binds to human or rat CB1R with an IC₅₀ of 0.3 and 0.4 nM, respectively, corresponding to a K_i value of 0.13 and 0.27 nM, respectively. Taranabant binds to the human or rat CB2R with an IC₅₀ value of 290 and 470 nM, respectively, corresponding to a K_i value of 170 and 310 nM, respectively. The selectivity ratio of CB1R over CB2R is approximately 1000-fold. Taranabant (MK-0364) is a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity. IC₅₀s of Taranabant for CB1R and CB2R by substituted amides is 0.3±0.1 nM, and 290±60 nM, respectively. Taranabant is a CB1R inverse agonist with minimal potential for covalent protein binding. Taranabant is an exceptionally potent and selective (900-fold over CB2) CB1R inverse agonist with >500-fold improvement in affinity over the original lead. In a functional assay of cyclic-AMP production, Taranabant is determined to be an inverse agonist (EC₅₀=2.4±1.4 nM).

In Vivo: Taranabant (MK-0364) dose-dependently inhibits 2 h and overnight food intake as well as overnight gains in body weight in C57BL/6N mice. At the 1- and 3-mg/kg doses (p.o.), Taranabant significantly inhibits 2-h food intake (36 and 69% reductions, respectively; P<0.05 and P<0.00001, respectively) and overnight food intake (13 and 40% reductions, respectively; P<0.05 and P<0.00001, respectively) as well as overnight gains in body weight (48 and 165% reductions, respectively; P<0.01 and P<0.00001, respectively). Taranabant dose-dependently inhibits food intake and weight gain, with an acute minimum effective dose of 1 mg/kg in diet-induced obese (DIO) rats. Taranabant (MK-0364) has a good pharmacokinetic profile in three species (rat, 1 mg/kg iv, 2 mg/kg po, F=74%, t_1/2=2.7 h; dog, 0.2 mg/kg iv, 0.4 mg/kg po, F=31%; t_1/2=14 h; rhesus monkey, 0.2 mg/kg iv, 0.4 mg/kg po, F=31%, t_1/2=3.6 h) and good brain exposure (1 mg/kg iv, brain and plasma concentrations of 0.11 and 0.18 μM at 1 h, respectively).

相关产品：Drug Repurposing Compound Library Plus  |  Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  GPCR/G Protein Compound Library  |  Neuronal Signaling Compound Library  |  Clinical Compound Library  |  Drug Repurposing Compound Library  |  WIN 55,212-2 Mesylate  |  Rimonabant Hydrochloride  |  AM251  |  JD-5037  |  SR144528  |  2-Arachidonoylglycerol  |  6-Iodopravadoline  |  Pregnenolone  |  β-Caryophyllene  |  Olivetol  |  Olorinab  |  N-Oleoyl glycine  |  Org 27569  |  CB1 antagonist 2  |  TM38837  |  Yangonin  |  Taranabant ((1R,2R)stereoisomer)  |  MDA 19  |  BML-190  |  2-Palmitoylglycerol  |  AM281  |  BAY 38-7271  |  CB2R PAM  |  Hemopressin (human, mouse)  |  Hemopressin(rat)

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。